Gaurav Guliani, MD
Neurology · Saint Paul, MNNPI 1659564946
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,190 of the $22,346 with a category attached, or 68.0%. AstraZeneca accounts for 71.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $17,035 and has fallen 98.9% since, to $184 in 2024. Among neurology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $413.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Tanabe Pharma America, Inc.$5K
- Argenx US, Inc.$1K
- UCB, Inc.$134
- Omniscient Neurotechnology America Ltd$118
- Philips North America LLC$58
Across 22 payments — averaging $4732.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orion Corporation$98K
- Tanabe Pharma America, Inc.$7K
What the payments were for
- Consulting fees$3,12814%
- Speaking & faculty fees$15,19068%
- Travel & lodging$2,63812%
- Food & beverage$1,3906%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $16,028 |
| Tanabe Pharma America, Inc. | 13 | $4,645 |
| Argenx US, Inc. | 3 | $1,363 |
| UCB, Inc. | 1 | $134 |
| Omniscient Neurotechnology America Ltd | 1 | $118 |
| Philips North America LLC | 2 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,346 in reported general payments places this provider in the 90th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 30 | $421,574 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 11 | $146,768 |
| CopaxoneGlatiramer Acetate | 12 | $88,632 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 22 | $26,723 |
| Pyridostigmine Bromide | 111 | $12,334 |
| Riluzole | 49 | $9,498 |
| Gabapentin | 231 | $6,855 |
| Mycophenolate Mofetil | 38 | $6,145 |
| Azathioprine | 57 | $4,676 |
| Duloxetine Hcl | 145 | $3,781 |
| Levetiracetam | 70 | $2,882 |
| Pregabalin | 68 | $2,373 |
| Baclofen | 65 | $1,625 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $1,323 |
| Prednisone | 127 | $1,095 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Paul
- Patricia PenovichSaint Paul$304K
- Ryan LeeSaint Paul$50K
- Jeffery AllenMinneapolis$1.1M
- Jonathan CalkwoodGolden Valley$493K
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
- Jessica HeiringGolden Valley$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.